530019 Stock Overview
Operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 3/6 |
Jubilant Pharmova Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,130.85 |
| 52 Week High | ₹1,309.00 |
| 52 Week Low | ₹408.60 |
| Beta | 1.56 |
| 11 Month Change | 0.34% |
| 3 Month Change | 24.80% |
| 1 Year Change | 169.57% |
| 33 Year Change | 88.44% |
| 5 Year Change | 118.86% |
| Change since IPO | 4,961.15% |
Recent News & Updates
Recent updates
Shareholder Returns
| 530019 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -3.1% | -0.2% | 0.3% |
| 1Y | 169.6% | 40.5% | 27.3% |
Return vs Industry: 530019 exceeded the Indian Pharmaceuticals industry which returned 40.5% over the past year.
Return vs Market: 530019 exceeded the Indian Market which returned 27.3% over the past year.
Price Volatility
| 530019 volatility | |
|---|---|
| 530019 Average Weekly Movement | 7.3% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in IN Market | 9.2% |
| 10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: 530019 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 530019's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1978 | 5,399 | Priyavrat Bhartia | www.jubilantpharmova.com |
Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of various diseases, including pulmonary embolism, cancer, coronary artery disease, and others.
Jubilant Pharmova Limited Fundamentals Summary
| 530019 fundamental statistics | |
|---|---|
| Market cap | ₹179.11b |
| Earnings (TTM) | ₹5.93b |
| Revenue (TTM) | ₹69.20b |
30.2x
P/E Ratio2.6x
P/S RatioIs 530019 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 530019 income statement (TTM) | |
|---|---|
| Revenue | ₹69.20b |
| Cost of Revenue | ₹23.90b |
| Gross Profit | ₹45.29b |
| Other Expenses | ₹39.36b |
| Earnings | ₹5.93b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Jan 31, 2025
| Earnings per share (EPS) | 37.45 |
| Gross Margin | 65.46% |
| Net Profit Margin | 8.57% |
| Debt/Equity Ratio | 47.7% |
How did 530019 perform over the long term?
See historical performance and comparison